If you look at the study protocols, they are planning to collect multiple blood tests at intervals after MSc infusions. Although there’s only 24 patients required in ICU , it can only be done properly in a space where the IcU is not over burdened I can see why they opted for digital because it’d be hard to sterilise a paper once in the space of contamination in Covid icu. anyways, I hope CYP management would look into expanding to other clinical sites in Melbourne especially. I believe that the reason CYP struggles to expand trials site is that there’s no existing convincing research that shows the reduction in mortality. Aussie docs are more conservative than Americans in trying out new unproven therapy. Once MSB interim results are released and shows positive result, more docs may show interests. it’s frustrating but this is a waiting game for a small company like this.
CYP Price at posting:
70.0¢ Sentiment: Buy Disclosure: Held
(20min delay)
